Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
TechOps Delivers Holiday Cheer With Record Bike and Toy Donations
ATLANTA, Georgia, Dec. 17 -- Delta Air Lines issued the following news on Dec. 16, 2025:
* * *
TechOps delivers holiday cheer with record bike and toy donations
On Dec. 10, Delta TechOps celebrated the holidays in a big way by presenting a record 2,123 bikes, over 3,000 new toys and a check for $50,000 from Delta to the Marine Toys for Tots Foundation Atlanta affiliate at a festive event at the TechOps Hangar in Atlanta. It was a record-breaking year with Delta exceeding both its bike and toy donation goals.
"This event truly embodies the spirit of TechOps. It's not just about donating funds
... Show Full Article
ATLANTA, Georgia, Dec. 17 -- Delta Air Lines issued the following news on Dec. 16, 2025:
* * *
TechOps delivers holiday cheer with record bike and toy donations
On Dec. 10, Delta TechOps celebrated the holidays in a big way by presenting a record 2,123 bikes, over 3,000 new toys and a check for $50,000 from Delta to the Marine Toys for Tots Foundation Atlanta affiliate at a festive event at the TechOps Hangar in Atlanta. It was a record-breaking year with Delta exceeding both its bike and toy donation goals.
"This event truly embodies the spirit of TechOps. It's not just about donating funds- year after year, our teams are proud to roll up their sleeves and build these bikes with care," said David Thompson, SVP of Delta TechOps. "Walking through the shops and seeing rows of bikes ready for local children is a powerful reminder of the generosity and teamwork that define us, not only during the holidays but throughout the year."
In addition to the Bike Drive, Delta G.O. employees from 16 departments across the business collected 3,036 toys this season to donate to Toys for Tots in Atlanta.
"We are deeply grateful to Delta Air Lines and its incredible team members for their extraordinary support as they proudly return for their 14th consecutive year as a National Corporate Sponsor of the Marine Toys for Tots Program," said retired Marine Lt. Gen. James B. Laster, president and CEO of the Marine Toys for Tots Foundation. "Delta's heartfelt bike and toy drives and generous contributions perfectly reflect the community service goals the Marine Corps has promoted for over 78 years through the Toys for Tots Program. Because of Delta's partnership, we will be able to deliver hope, smiles and Christmas magic to less fortunate children across America."
Delta is proud to be the Airline Partner of Toys for Tots and a National Corporate Sponsor of the Marine Toys for Tots Literacy Program. The Literacy Program's mission offers disadvantaged children the ability to compete academically and to succeed in life by providing books to enhance their ability to read and communicate effectively. Delta contributes $775,000 annually to Toys for Tots at the national level and in select focus market chapters with Toys for Tots toy drives held annually in many locations systemwide.
From Seattle to Salt Lake City, Boston to JFK, TechOps teams came together to host Holiday in the Hangar events, build bikes and collect toys for children in need. "These efforts show that no matter where we are, Delta people share the same commitment to making a difference in their communities," said Thompson.
At JFK, the Delta TechOps team hosted its Holiday in the Hangar event in partnership with the Community Mayors for Children with Special Needs, an all-volunteer 501(c)(3) dedicated to creating opportunities for mentally and physically challenged children to experience and enjoy numerous activities designed to accommodate their needs and lift their spirits. Over 4,000 children from all over New York filled the JFK hangar and Santa Claus rode in on Delta aircraft to wish everyone a Merry Christmas. This cross-divisional, community event is one the team looks forward to every year.
BOS celebrated its 11th Holiday in the Hangar with Make-A-Wish and Boston Children's Hospital -- the team's largest event to date, welcoming more than 900 guests. This beloved tradition began in 2009 after the Delta-Northwest merger and continues to bring joy to families each holiday season.
Generosity was on full display: BOS employees donated enough toys to fill six bag carts, prompting an extra drop-off at Boston Children's Hospital. Over 100 volunteers from every division pitched in to make the day unforgettable.
SEA TechOps has supported the local Toys for Tots chapter for 12 years, building and delivering bikes to children in need. This year, in honor of Delta's centennial, the team raised enough to purchase 100 bikes -- a record contribution.
The team also plays a key role in Holiday in the Hangar, a tradition since 2011 that gives families a magical "flight to the North Pole." Kids receive gifts from Santa and Mrs. Claus, enjoy crafts, games, model trains, Flight Deck tours and photos from Santa's sleigh to inside a plane engine. Guests meet athletes from the Seahawks, Sounders and Sea Wolves, while enjoying fire engine tours and canine demos from the Port of Seattle teams.
Employees make this event possible by donating gifts and volunteering. This year, Seattle TechOps partnered with the YMCA of Kent, Washington, to spread even more holiday joy.
In SLC, the TechOps team hosted its 12th and largest Holiday in the Hangar event for Children's Miracle Network Hospitals. The team donated 130 gifts for patients and their families and raised $105,000 to give to Primary Children's Hospital. SLC's Toys for Tots bike drive team bought, built and donated 120 bikes thanks to over $5,500 in employee donations.
These are just a few examples of the incredible volunteer work and holiday events hosted by Delta divisions and teams across the system. Whether it's supporting Toys for Tots, partnering with local charities, or volunteering time and talent, Delta people prove that no one better connects the world, starting with our communities.
* * *
Original text here: https://news.delta.com/techops-delivers-holiday-cheer-record-bike-and-toy-donations
[Category: BizTravel]
Sedgwick Forecasts 2026 in New Global Risk Study
MEMPHIS, Tennessee, Dec. 17 (TNSrep) -- Sedgwick, a provider of technology-enabled risk and benefit solutions, issued the following news release:
* * *
Sedgwick forecasts 2026 in new global risk study
Company experts and Fortune 500 executives share key predictions across sectors
*
Sedgwick, the world's leading risk and claims administration partner, has published its 2026 forecasting report (https://www.sedgwick.com/global-risk-report/?utm_source=pr). The report identifies key trends across sectors supported by insights from the company's industry leaders and Fortune 500 executives to spotlight
... Show Full Article
MEMPHIS, Tennessee, Dec. 17 (TNSrep) -- Sedgwick, a provider of technology-enabled risk and benefit solutions, issued the following news release:
* * *
Sedgwick forecasts 2026 in new global risk study
Company experts and Fortune 500 executives share key predictions across sectors
*
Sedgwick, the world's leading risk and claims administration partner, has published its 2026 forecasting report (https://www.sedgwick.com/global-risk-report/?utm_source=pr). The report identifies key trends across sectors supported by insights from the company's industry leaders and Fortune 500 executives to spotlightthe challenges and opportunities that will define the future of risk, claims, and workplace resilience.
In preparing the report, Sedgwick conducted research, sourced trends from company experts, and surveyed executives across Fortune 500 companies in partnership with an external research provider. The data and content focus on ensuring organizations are aware of new risks, prepared to adapt to existing and emerging challenges across industries, and navigate evolving trends while ensuring success in 2026.
"Navigating risk in 2026 is about planning for what you don't know is coming, not just what keeps you up at night right now," said Mike Arbour, CEO, Sedgwick. "This report should serve as a guide for companies across industries. Preparation, resilience, and long-term success is contingent upon having a full spectrum understanding of the present and future risk."
The 2026 forecasting report highlights trends and data relating to:
* AI Risk, Readiness and Governance
- As AI rapidly reshapes claims and risk, organizations cited the rapid pace of AI advancements as the leading implementation challenge. Regulatory uncertainty is a significant hurdle, and companies are rapidly establishing strong governance and oversight.
- Key data from the Fortune 500 external survey include:
= 70% report having AI risk committees in place
= 14% are fully prepared for AI deployment
= 31% struggle to keep pace or are behind in AI preparation
* Catastrophe Risks and Recovery Challenges
- Extreme weather, property exposure, and labor shortages are driving up costs, stretching timelines, and adding new layers of complexity and risk to all industries. Agility, proactive planning, and technology are critical amid shifting risk profiles.
= Key data from the Fortune 500 external survey include:
= 75% are experiencing some degree of labor friction due to immigration-related access hindrance
= 11% are experiencing severe critical or severe labor access challenges due to immigration-related impact
= 76% expect moderate to severe insurance pressure from CAT challenges
* Supply Chain Disruption and Adaptation
- Supply chain risk is being exacerbated by geopolitical instability, shifting trade policies, regulatory upheaval, and global events. Consistent challenges have emerged from supplier concentration, logistic disruptions, and cyber threats.
= Key data from the Fortune 500 survey include:
= 66% report negative impact from U.S. trade policies
= 65% cite economic and geopolitical volatility as primary supply chain concern
= 38% flag cybersecurity as structural supply chain vulnerability
* Workforce Transformation and Talent Management
- Companies must reimagine leadership, focusing on people skills, team-building, career mobility and purposeful mentorship as AI brings both challenges and opportunities.
= Key data from the Fortune 500 external survey include:
= 32% cited changing employee expectations as the leading talent challenge
= 47% cited difficulties in transferring leadership skills as a barrier to success
= 20% cited VR/AR as a priority tool in reducing injuries
* Global Risk and Resilience
- Persistent instability is the hallmark of global risk strategies now and in 2026. Organizations face relentless volatility from a number of sources, often all at once. As risk exposures rise faster than preparedness, agile scenario planning and staged interventions will be critical moving forward.
= Key data from the Fortune 500 external survey include:
= 3% of organizations are fully prepared for all global risks
= 56% cited geopolitical instability as the top risk; this was the single highest concern across all sectors and regions
= 50% cited cyber as a critical risk exposure
"Anticipating what's next and navigating the unexpected will be the differentiators between success and failure in 2026," said Dave Arick, Managing Director, Global Risk Management, Sedgwick. "At Sedgwick, we are prepared and ready to empower organizations and clients to adapt, innovate, and thrive in a rapidly evolving world."
The trends, predictions, and data in the forecasting 2026 report will be monitored by Sedgwick's experts throughout the year. For more information, visit sedgwick (https://www.sedgwick.com/global-risk-report/?utm_source=pr).
* * *
About Sedgwick
Sedgwick is the world's leading risk and claims administration partner, helping clients thrive by navigating the unexpected. The company's expertise, combined with the most advanced AI-enabled technology available, sets the standard for solutions in claims administration, loss adjusting, benefits administration and product recall. With over 33,000 colleagues and 10,000 clients across 80 countries, Sedgwick provides unmatched perspective, caring that counts, and solutions for the rapidly changing and complex risk landscape. Sedgwick's majority shareholder is The Carlyle Group; Stone Point Capital LLC, Altas Partners, CDPQ, Onex and other management investors are minority shareholders. For more, see sedgwick.
* * *
Original text here: https://www.sedgwick.com/press-release/sedgwick-forecasts-2026-in-new-global-risk-study/
[Category: BizInsurance]
Marcus & Millichap Facilitates $6.5M Sale of 36-Unit Senior Housing Property in Faribault, Minnesota
ENCINO, California, Dec. 17 -- Marcus and Millichap issued the following news release:
* * *
Marcus & Millichap Facilitates $6.5M Sale of 36-Unit Senior Housing Property in Faribault, Minnesota
FARIBAULT, Minn., Dec. 16, 2025 - Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of Pleasant View Estates, a 36-unit assisted living and memory care facility in Faribault, Minnesota, for $6.5 million.
"This acquisition reflects growing investor confidence in the seniors
... Show Full Article
ENCINO, California, Dec. 17 -- Marcus and Millichap issued the following news release:
* * *
Marcus & Millichap Facilitates $6.5M Sale of 36-Unit Senior Housing Property in Faribault, Minnesota
FARIBAULT, Minn., Dec. 16, 2025 - Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of Pleasant View Estates, a 36-unit assisted living and memory care facility in Faribault, Minnesota, for $6.5 million.
"This acquisition reflects growing investor confidence in the seniorshousing sector," said Ray Giannini, senior managing director investments. "The attached, vacant skilled nursing facility will be repurposed into additional assisted living units, enhancing the property's value and aligning with market demand. We're seeing strong momentum in this market, with improvements across all key metrics driving increased activity from both buyers and sellers.
Giannini, investment specialist in Marcus & Millichap's Milwaukee office, had the exclusive listing to market the property on behalf of the seller, Monarch Healthcare Management, and procured the buyer, a regional private investor.
Pleasant View Estates, located at 41 Brand Ave., was built in 1998 and sits on 4.82 acres. The 44,300-square-foot facility includes 24 one-bedroom and 12 two-bedroom apartment-style units. Approximately 75% of the residents are Medicaid assisted living facility occupants. The building is connected to a vacant skilled nursing facility formerly known as Pleasant Manor.
* * *
About Marcus & Millichap, Inc. (NYSE: MMI)
Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. As of December 31, 2024, the company had 1,712 investment sales and financing professionals in over 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate. The company also offers market research, consulting and advisory services to clients. Marcus & Millichap closed 7,836 transactions in 2024, with a sales volume of approximately $49.6 billion. For additional information, please visit www.MarcusMillichap.com.
* * *
Original text here: https://www.marcusmillichap.com/news-events/press/2025/12/12-16-pleasantviewestates
[Category: BizRealEstate]
Littler Issues Commentary: Much Ado About OSHA Interpretation Letters
SAN FRANCISCO, California, Dec. 17 -- Littler, a law firm, issued the following commentary on Dec. 16, 2025:
* * *
Much Ado About OSHA Interpretation Letters
By Peter Vassalo and Colleen Koehler
There has been much ado about compliance assistance from the United States Department of Labor (DOL) this year. With these expanded opportunities, employers should consider seeking guidance on application of OSHA standards to their unique work environments.
The DOL's Occupational Safety and Health Administration (OSHA) published a news release on December 10, 2025, calling attention to seven letters
... Show Full Article
SAN FRANCISCO, California, Dec. 17 -- Littler, a law firm, issued the following commentary on Dec. 16, 2025:
* * *
Much Ado About OSHA Interpretation Letters
By Peter Vassalo and Colleen Koehler
There has been much ado about compliance assistance from the United States Department of Labor (DOL) this year. With these expanded opportunities, employers should consider seeking guidance on application of OSHA standards to their unique work environments.
The DOL's Occupational Safety and Health Administration (OSHA) published a news release on December 10, 2025, calling attention to seven lettersof interpretation--addressing topics from Covid-19 to confined space--intended "to ensure the consistent and transparent application of federal workplace safety and health standards."
This news release follows the DOL's announcement on June 2, 2025, of a newly launched opinion letter program under Deputy Secretary of Labor Keith Sonderling (confirmed March 12, 2025) that "expands the department's longstanding commitment to providing meaningful compliance assistance" and involves five key enforcement agencies, including OSHA. Different agencies issue different forms of compliance guidance with varying legal significance. From OSHA, we can expect "letters of interpretation" (LOI), which give a requester OSHA's take on how its standards would apply to worksite-specific conditions.
The seven interpretation letters referenced in OSHA's recent news release were published between January 3 and June 17, 2025, and conclude with a disclaimer: "OSHA's requirements are set by statute, standards, and regulations. Our letters of interpretation do not create new or additional requirements but rather explain these requirements and how they apply to particular circumstances." While LOIs are intended solely to provide guidance to employers, an employer's reliance on an OSHA LOI can help ensure that in the event of an inspection, OSHA will be consistent in applying its standards to an individual workplace condition. In other words, if OSHA issues a citation for an approach that was "blessed" in an interpretation letter, the interpretation letter may provide grounds to have the citation vacated. Most importantly, an interpretation letter from OSHA can take the guess work out of planning for compliance, especially with performance-based standards under which employers must identify the specific equipment or methods of achieving a prescribed objective.
Regardless of whether the 2025 OSHA interpretation letters apply to one's business, the DOL's emphasis on providing regulatory guidance is welcome news for employers. OSHA interpretation letters can be helpful in planning for compliance with the Occupational Safety and Health Act, and when evaluating or challenging an OSHA citation. Past interpretation letters are available on a new landing page. There's no need to observe from a distance, however. OSHA's general policy is to publish all LOIs in response to questions from the regulated community.
Given the DOL's embrace of interpretation letters, employers should consider taking a proactive approach on thorny compliance issues by requesting OSHA's interpretation of potentially applicable safety standards. To alleviate concern that requesting an interpretation letter could trigger an inspection, businesses can retain counsel who can submit a request without disclosing the business's identity. Therefore, employers interested in anonymously soliciting an interpretation letter from OSHA should consult with employment counsel.
* * *
Authors
Peter Vassalo
Senior Counsel
Washington, D.C.
* * *
Colleen Koehler
Associate
Columbus
* * *
Original text here: https://www.littler.com/news-analysis/asap/much-ado-about-osha-interpretation-letters
[Category: BizLaw/Legal]
Littler Issues Commentary: Determining Work Authorization for Employees on TPS and Humanitarian Parole - Updated December 16, 2025
SAN FRANCISCO, California, Dec. 17 -- Littler, a law firm, issued the following commentary on Dec. 16, 2025:
* * *
Determining Work Authorization for Employees on TPS and Humanitarian Parole - Updated December 16, 2025
By Jorge Lopez and Tasneem Zaman
The Trump administration has enacted significant policy changes impacting individuals authorized to work under various immigration programs, including Temporary Protected Status (TPS), humanitarian parole, and the CHNV programs. We created a chart intended to assist employers in determining the work authorization status of employees who have presented
... Show Full Article
SAN FRANCISCO, California, Dec. 17 -- Littler, a law firm, issued the following commentary on Dec. 16, 2025:
* * *
Determining Work Authorization for Employees on TPS and Humanitarian Parole - Updated December 16, 2025
By Jorge Lopez and Tasneem Zaman
The Trump administration has enacted significant policy changes impacting individuals authorized to work under various immigration programs, including Temporary Protected Status (TPS), humanitarian parole, and the CHNV programs. We created a chart intended to assist employers in determining the work authorization status of employees who have presentedan Employment Authorization Document (EAD) issued by the Department of Homeland Security (DHS) under one of these programs.
This chart has been updated to note developments concerning Ethiopia.
Several federal lawsuits are currently pending across the United States, challenging the government's decision to terminate these programs. As a result, the information provided here is subject to change based on the outcomes of these legal proceedings.
* * *
Authors
Jorge R. Lopez
Shareholder
Miami
* * *
Tasneem Zaman
Senior Counsel
Washington, D.C.
* * *
Original text here: https://www.littler.com/news-analysis/asap/determining-work-authorization-employees-tps-and-humanitarian-parole-updated-2
[Category: BizLaw/Legal]
Hilton To Expand Luxury Footprint With LXR Hotels & Resorts in Turks and Caicos With AMARIS Grace Bay
MCLEAN, Virginia, Dec. 17 -- Hilton Worldwide Holdings posted the following news release on Dec. 16, 2025:
* * *
Hilton To Expand Luxury Footprint with LXR Hotels & Resorts in Turks and Caicos with AMARIS Grace Bay
Slated to open in 2028, the bespoke luxury resort and branded residences will showcase refined design, authentic character, and a commitment to sustainable elegance in the heart of the Caribbean
*
TURKS AND CAICOS and MIAMI - Hilton (NYSE: HLT) today announced the signing of AMARIS Grace Bay to its exclusive LXR Hotels & Resorts portfolio, a distinctive resort and residential development
... Show Full Article
MCLEAN, Virginia, Dec. 17 -- Hilton Worldwide Holdings posted the following news release on Dec. 16, 2025:
* * *
Hilton To Expand Luxury Footprint with LXR Hotels & Resorts in Turks and Caicos with AMARIS Grace Bay
Slated to open in 2028, the bespoke luxury resort and branded residences will showcase refined design, authentic character, and a commitment to sustainable elegance in the heart of the Caribbean
*
TURKS AND CAICOS and MIAMI - Hilton (NYSE: HLT) today announced the signing of AMARIS Grace Bay to its exclusive LXR Hotels & Resorts portfolio, a distinctive resort and residential developmentset to debut in 2028 on the world-renowned Grace Bay Beach. Located along pristine shores, AMARIS brings a new dimension of curated luxury to Turks & Caicos, offering travelers an intimate escape defined by exceptional design and personalized service. AMARIS Grace Bay, LXR Hotels & Resorts is owned by SEFAMM (TCI) Ltd.
Situated along one of the planet's most breathtaking shorelines, AMARIS Grace Bay will rise as a captivating presence that blends contemporary Caribbean design and sophistication. This mixed-use retreat will feature 170 elegantly appointed guest rooms and suites, including one-to-four-bedroom branded residences, each framing sweeping views of the iconic turquoise bay.
The resort's design draws inspiration from the rich tones and textures of its natural surroundings, incorporating tactile materials such as woven fabrics and polished wood to create a seamless connection between interior spaces and the environment. A stunning contemporary design ethos will fuse natural textures with modern aesthetics, reflecting the island's beauty.
"AMARIS Grace Bay, LXR Hotels & Resorts in Turks and Caicos, joins a lineup of exceptional developments across the Caribbean and Latin America, including the recently announced Waldorf Astoria Turks and Caicos Dellis Cay. The strategic additions to Hilton's expanding pipeline in Turks and Caicos strengthen Hilton's commitment to accelerating growth in high-demand luxury markets," said Pablo Maturana, vice president of development, architecture, design and construction, Caribbean and Latin America, Hilton. "AMARIS Grace Bay is a perfect addition to the LXR portfolio, reflecting Hilton's vision to curate world-class experiences in the region's most coveted destinations. As we continue to grow our presence, we are proud to introduce iconic properties that will celebrate the rich culture and natural beauty of each locale."
Guests and residents will be invited to savor exceptional dining across two specialty restaurants, an Aegean-meets-Caribbean beachfront restaurant and a Japanese Grill with omakase counter, paired with signature bars serving refreshing, convivial cocktails and light bites.
Dedicated pool and beach service will ensure effortless relaxation while wellness enthusiasts will be able to rejuvenate at a state-of-the-art spa and fitness center spanning nearly 10,000 square feet. Social, groups and incentive travelers will appreciate an intimate 970-square-foot event space ideal for meetings and gatherings. Families and little adventurers will be well catered to with a fully equipped kids' club and game room, creating memorable moments for every guest.
"Our vision for AMARIS Grace Bay was to create an enclave that feels both timeless and deeply connected to the extraordinary beauty of Grace Bay. We are crafting an experience of sustainable elegance and refined comfort. LXR Hotels & Resorts is a partner that champions the individuality and authentic spirit we are bringing to life," said Fio Firat Mayil, founder and president, SEFAMM (TCI) Ltd.
AMARIS Grace Bay will redefine the Caribbean escape as a vibrant cultural and social hub, inviting travelers, residents and locals to connect deeply with the spirit of Turks and Caicos. Through the brand's signature Pursuit of Adventure program, guests will embark on immersive experiences, from curated on-property activities to exclusive excursions, crafted to celebrate the island's heritage and natural beauty. The atmosphere will blaze with energy: rhythmic drumbeats and the call of the conch shell mingle with the scent of sea salt, while touches of light and bonfires on the beach for culinary events create spaces for storytelling and connection. Every detail will honor local traditions while embracing Hilton's commitment to responsibility, championing eco-conscious practices, sourcing locally, and fostering meaningful engagement with the community.
"The signing of AMARIS Grace Bay marks an exciting milestone for LXR Hotels & Resorts and Branded Residential by Hilton portfolio as we introduce our brand to one of the Caribbean's most iconic destinations. Grace Bay's effortless beauty and vibrant culture provide the perfect backdrop for a property that blends elevated design, immersive experiences, and refined residential living," said Feisal Jaffer, global head, LXR Hotels & Resorts, Hilton. "As we continue to selectively grow our global collection, our focus remains on curating independent, one-of-a-kind properties in strategic destinations across the Caribbean and Latin America and beyond."
A future of luxury for the Caribbean and Latin America
Hilton is expanding at record pace across the Caribbean and Latin America (CALA), with nearly 300 hotels in more than 35 countries and territories. Across the region, the luxury and lifestyle portfolio spans over 100 hotels, including boutique properties added through a strategic partnership with Small Luxury Hotels of the World (SLH). Additionally, the company has approximately 160 hotels in the CALA pipeline, the largest in its history for the region, including 50 in the luxury and lifestyle categories. Hilton plans to continue expanding its luxury portfolio, including its iconic brands Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, and LXR Hotels & Resorts, with the goal of nearly doubling its presence across these three brands.
Recent milestones include the grand opening of the highly anticipated Waldorf Astoria Costa Rica Punta Cacique, the brand's debut in the country, and the announcement of Waldorf Astoria Turks and Caicos Dellis Cay, set to open in 2028. In Mexico, Hilton plans to debut Waldorf Astoria San Miguel de Allende in 2027, followed by Conrad Los Cabos in 2028.
AMARIS Grace Bay, LXR Hotels & Resorts will offer guests the benefits of Hilton Honors, the award-winning guest-loyalty program for Hilton's distinct hotel brands.
For additional Hilton development news, please visit stories.hilton.com.
* * *
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 25 world-class brands comprising 9,000 properties and over 1.3 million rooms, in 141 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed over 3 billion guests in its more than 100-year history. Named as the No. 1 World's Best Workplace by Great Place to Work and Fortune, Hilton aims to create the best culture for its 500,000 team members around the world. Hilton has introduced industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 235 million Hilton Honors members who book directly with Hilton can earn Points for hotel stays and experiences money can't buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, X, LinkedIn, Instagram and YouTube.
* * *
About LXR Hotels & Resorts
LXR Hotels & Resorts is a growing collection of 16 award-winning luxury properties that celebrate the timeless pursuit of personal adventure. Found in the world's most alluring destinations, each hand-selected property boasts its own storied past and is infused with the essence of its distinctive locale, providing a luxurious hub for the discerning adventurer. As part of its commitment to enriching the guest experience, LXR Hotels & Resorts celebrates experiential travel with the Pursuit of Adventure, a new brand signature that immerses guests in authentic, curated experiences that reflect the unique culture and character of each destination. LXR Hotels & Resorts is part of Hilton, a leading global hospitality company. Each property benefits from the strength of the Hilton enterprise and its award-winning Hilton Honors program. Experience an inspiring stay at LXR Hotels & Resorts by booking at lxrhotels.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about LXR Hotels & Resorts at stories.hilton.com/lxr and follow the brand on Instagram and Facebook.
* * *
Branded Residential by Hilton
Branded Residential by Hilton extends the light and warmth of hospitality for which Hilton is known worldwide, creating opportunities to own real estate at globally renowned properties in the world's most desirable locations. Branded Residential by Hilton delivers an elevated offering, rooted in a philosophy of care and attention to the resident experience across categories, with success across all market segments, from luxury to lifestyle and beyond. With 12 world-class brands spanning 39 properties and over 6,000 units operating globally, and another 41 properties and approximately 5,000 units in development, Branded Residential by Hilton brings Hilton's century of influence and expertise in global hospitality to a culturally-savvy, design-forward and diverse, best-in-class residential portfolio. Learn more at hiltonbrandedresidences.com.
* * *
Original text here: https://stories.hilton.com/releases/hilton-to-expand-luxury-footprint-with-lxr-hotels-resorts-in-turks-and-caicos-amaris-grace-bay
[Category: BizTravel]
Exdensur Approved by US FDA for the Treatment of Severe Asthma
LONDON, England, Dec. 17 (TNSjou) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2025:
* * *
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
* Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype
* Approval based on SWIFT trials showing significantly lower rate of annualised asthma exacerbations in patients receiving depemokimab versus placebo
* SWIFT data included reduction in exacerbations requiring
... Show Full Article
LONDON, England, Dec. 17 (TNSjou) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2025:
* * *
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
* Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype
* Approval based on SWIFT trials showing significantly lower rate of annualised asthma exacerbations in patients receiving depemokimab versus placebo
* SWIFT data included reduction in exacerbations requiringhospitalisation and/or emergency department visits with depemokimab
* An estimated 2 million Americans live with severe asthma and 50% continue to experience frequent exacerbations and hospitalisations requiring novel solutions
*
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients aged 12 years and older.
The FDA approval of Exdensur is based on data from the SWIFT-1 and SWIFT-2 phase III trials. In these studies, depemokimab demonstrated sustained exacerbation reduction with two doses per year versus placebo, both plus standard of care. Treatment with depemokimab resulted in a significant 58% and 48% reduction in the rate of annualised asthma exacerbations (asthma attacks) over 52 weeks from SWIFT-1 and SWIFT-2, respectively [rate ratio (95% confidence interval) p-value: SWIFT-1 0.42 (0.30, 0.59) p<0.001 and SWIFT-2 0.52 (0.36, 0.73) p<0.001] (AER depemokimab versus placebo: SWIFT-1 0.46 vs. 1.11 and SWIFT-2 0.56 vs. 1.08 exacerbations per year)./1
In a secondary endpoint from SWIFT-1 and SWIFT-2, patients treated with depemokimab experienced numerically fewer exacerbations requiring hospitalisation and/or emergency department visits (1% and 4%) compared with placebo (8% and 10%), respectively. A pre-specified pooled analysis of the two trials showed there was a 72% reduction in the annualised rate of clinically significant exacerbations requiring hospitalisation and/or ED visits over 52 weeks for depemokimab compared with placebo [rate ratio 0.28, 95% CI (0.13, 0.61), nominal p=0.002] (AER depemokimab 0.02 versus placebo 0.09). Across these trials, depemokimab was well-tolerated, with patients experiencing a similar rate and severity of side effects as those receiving placebo./1
Kaivan Khavandi, SVP & Global Head, Respiratory, Immunology & Inflammation R&D, GSK said: "Physicians in the US now have the option to provide sustained protection from exacerbations for patients living with severe asthma with an eosinophilic phenotype in just two doses a year. Exdensur could redefine patient care and further establish the use of biologics for those who continue to experience exacerbations despite treatment."
Depemokimab is a novel therapy that has been developed with an extended half-life, enabling the sustained suppression of disease-driving type 2 inflammation with twice-yearly dosing./1 These distinct properties could potentially improve patient outcomes while reducing health system burden.
An estimated 2 million Americans live with severe asthma and half continue to experience frequent exacerbations that may lead to hospitalisations, emergency department visits and corresponding increased health system costs./2,3,4 While biologics have demonstrated benefit in controlling severe asthma, only 20% of eligible patients in the US currently receive one, increasing their risk of exacerbations and worsening disease./5 Longer dosing intervals have been associated with an increased likelihood that patients would consider a biologic and 73% of physicians believe it would be beneficial./6,7
Geoffrey Chupp, MD, Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine, Yale University said: "Current biologic treatments for asthma are often underutilised and frequent injections can be inconvenient for many patients and lead to inconsistent use. There is clearly an opportunity to provide a longer duration of protection from exacerbations between injections for severe asthma patients that reduces the frequency of doses and may improve overall health care utilisation. Exdensur could empower physicians and patients to potentially achieve their treatment goals with fewer injections."
Tonya Winders, President and CEO, Global Allergy & Airways Patient Platform said: "The struggle for people living with severe asthma is immense, with many silently enduring continued symptom recurrence and exacerbations. An innovative treatment option like Exdensur that offers the long-acting protection from exacerbations that severe asthma patients with an eosinophilic phenotype deserve, with the benefit of fewer doses, is truly welcome."
Depemokimab recently received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and a positive CHMP opinion in Europe, with an approval decision expected in Q1 2026. Regulatory submissions are also under review across the globe, including in China and Japan.
* * *
About severe asthma
Severe asthma is defined as asthma that requires treatment with medium- to high-dose inhaled corticosteroids plus a second therapy (i.e., systemic corticosteroid or biologic) to prevent it from becoming uncontrolled, or which remains uncontrolled despite therapy./8 Type 2 inflammation is the underlying cause of pathology in more than 80% of patients with severe asthma, in which patients exhibit elevated levels of eosinophils (a type of white blood cell)./9
* * *
About Exdensur (depemokimab-ulaa)
Exdensur is the first ultra-long-acting biologic being evaluated for certain respiratory diseases with underlying type 2 inflammation, such as severe asthma. It has been developed with an extended half-life to enable twice-yearly dosing./1
Please see accompanying US Prescribing Information here (https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Exdensur/pdf/EXDENSUR-PI-PIL.PDF).
* * *
About the SWIFT phase III trials
Results from the SWIFT trials were presented at the 2024 European Respiratory Society International Conference and published in the New England Journal of Medicine (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2406673)./1
The SWIFT-1 and SWIFT-2 clinical trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 participants with severe asthma who were randomised to receive depemokimab or a placebo respectively, in addition to their standard of care (SOC) treatment with medium to high-dose inhaled corticosteroids plus at least one additional controller. The full analysis set in SWIFT-1 included 250 patients in the depemokimab plus SOC arm and 132 in the placebo plus SOC arm; in SWIFT-2, 252 patients were included in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm./1
* * *
About the depemokimab development programme
The phase III programme consists of SWIFT-1 and SWIFT-2 in severe asthma, with an open label extension study (AGILE), and the ANCHOR-1 and ANCHOR-2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP)./1,10,11 Depemokimab is currently being evaluated in phase III trials for the treatment of other diseases with underlying type 2 inflammation, including OCEAN for EGPA and DESTINY for HES./12,13 GSK has also initiated the ENDURA-1, ENDURA-2 and VIGILANT phase III trials assessing the efficacy and safety of depemokimab as an add-on therapy in patients with uncontrolled moderate to severe COPD with type 2 inflammation./14
About GSK in respiratory
GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics and inhaled medicines, GSK is focused on improving outcomes and the lives of people living with all types of asthma and COPD, along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q3 Results for 2025.
* * *
References
1./ Jackson, David J., et al. "Twice-yearly Depemokimab in severe asthma with an eosinophilic phenotype." New England Journal of Medicine, vol. 391, no. 24, 19 Dec. 2024, pp. 2337-2349, https://doi.org/10.1056/nejmoa2406673.
2./ Wang, Eileen, et al. "Characterization of severe asthma worldwide." CHEST, vol. 157, no. 4, Apr. 2020, pp. 790-804, https://doi.org/10.1016/j.chest.2019.10.053.
3./ Menzies-Gow, Andrew, et al. "A renewed charter: Key principles to improve patient care in severe asthma." Advances in Therapy, vol. 39, no. 12, 17 Oct. 2022, pp. 5307-5326, https://doi.org/10.1007/s12325-022-02340-w. .
4./ "Cost of Asthma on Society." Cost of Asthma on Society, Asthma & Allergy Foundation of America, 31 Jan. 2025, https://www.aafa.org/advocacy/key-issues/access-to-health-care/cost-of-asthma-on-society.
5./ Park, Jihye, et al. "Unmet treatment needs in asthma patients with eosinophilic phenotype: A US claims-based study on asthma exacerbations and Healthcare Resource Utilization." CHEST, vol. 166, no. 4, Oct. 2024, https://doi.org/10.1016/j.chest.2024.06.2816.
6./ Tal-Singer, Ruth, et al. "Disease impact and perception of biologics in adults with type 2 inflammation respiratory disease: International survey results." Patient Preference and Adherence, Volume 19, Apr. 2025, pp. 1159-1170, https://doi.org/10.2147/ppa.s517466.
7./ Research Partnership Quant uptake Market Research, 200 HCPs Top two box on a seven-point scale where seven equaled "highly beneficial".
8./ Brussino, Luisa, et al. "Is it severe asthma or asthma with severe comorbidities?" Journal of Asthma and Allergy, Volume 10, Nov. 2017, pp. 303-305, https://doi.org/10.2147/jaa.s150462.
9./ Heaney, Liam G., et al. "Eosinophilic and noneosinophilic asthma." CHEST, vol. 160, no. 3, Sept. 2021, pp. 814-830, https://doi.org/10.1016/j.chest.2021.04.013.
10./ "An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE)." ClinicalTrials.gov, GlaxoSmithKline, clinicaltrials.gov/study/NCT05243680. Accessed 8 Dec. 2025.
11./ Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, Maspero J, Fujieda S, Zhang L, Sousa AR, Woods SJ, Davis AM, Schalkwijk S, Edwards D, Ranganathan P, Follows R, Marshall C, Han JK; ANCHOR-1 and ANCHOR-2 trial investigators. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet. 2025 Mar 15;405(10482):911-926. doi: 10.1016/S0140-6736(25)00197-7.
12./ "Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)." ClinicalTrials.gov, GlaxoSmithKline, clinicaltrials.gov/study/NCT05263934. Accessed 8 Dec. 2025.
13./ Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY)." ClinicalTrials.gov, GlaxoSmithKline, clinicaltrials.gov/study/NCT05334368. Accessed 8 Dec. 2025.
14./ Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) (ENDURA -1)." ClinicalTrials.Gov, GlaxoSmithKline, clinicaltrials.gov/study/NCT06959095. Accessed 8 Dec. 2025.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma/
[Category: BizPharmaceuticals]
